Last December 2013 I asked Gerald at the Conference in L.A.

New Post Public Reply Private Reply Replies (1) Message Board
Daveludlow
Last December 2013 I asked Gerald at the Conference in L.A. if "shareholders would be happy by February." At that time we needed to get above .10 cents for 20 consecutive days in order to get the 5 or 10 million warrant money we needed to keep things going. Gerald responded, "Oh, we'll be in great shape by the U.N. Conference at the end of January." He further said they had a lot of catalysts coming after the first of the year.

It is true, in the first half of January the pps did spike up to .138 cents due to our anticipation of a LymPro Partnership. Many of us were expecting a JV partnership for Lympro with large up front money. Back in Sept of 2013 Gerald told me in Las Vegas regarding our LymPro partner: "Someone might pay you x now, but down the road be willing to pay you 100x." That is where I first got the notion of a "classic partner" for Lympro with up front money.

But at the SF Conference on January 15th, Gerald announced we had discovered some "codes" for reimbursement that would increase LymPro's net present value many times. And as a result, we would not be pursuing a Lympro partner in the immediate future. The stock price immediately started falling from .138 cents to below .07 cents. (Yet, I have never heard Gerald refer to these important codes since that occasion, nor seen the increase in net present value!)

The pps remained low until May when Gerald announced they had "identified" a Lympro partner but were still finalizing the details and wouldn't announcement the agreement until after the July Conferences in order to gain additional "leverage." The pps went from .07 cents to .193 cents on July 30th in anticipation of the LymPro data that preceded the LymPro partnership announcement. We all know what happened on July 31st. We dropped from .193 cents to .12 cents.

In August we held out hope for the LymPro data and the JV partnership announcement in September, the "end of summer." Instead, we got a master service agreement with ICON instead of a "classic partner" and the pps fell from .12 cents down to the .087 cents where we are now.

So, with all that said, many of us feel Gerald has left us at the altar a few times this year and as a result....feel anxiety over his promises that have managed to elusively slip away. During 2014.... we started at around .08 or .09 cents, and after many fits and starts....we are still there. So I would ask the people on the board who frequently lecture some of us longs that have criticisms....to be patient with us. Some of us are in a position where our investment is maybe larger than it should be for our overall net worth. As a result, we do care about the near term pps, not just what AMbS will be worth in 4 or 5 years. Please be patient with us and not lecture us about being over invested in this high risk stock. There are all sorts of people and situations and reasons why people invest the way they do.

The concerns I have raised this past month, and that JP has raised recently, and others as well, are not because we are flippers like Solantey, it is because we have genuine concerns. It doesn't mean we aren't solidly with you in our love of Gerald and belief in AMBS. We just have different expectations and time frames than you do.

Obviously, I sometimes get emotional and overstate things. I apologize for that. I will try to reign in the intensity. But my posts have been genuine. If dissenting and contrary views are presented on this board, in a polite way, they should be treated respectfully. I'll try not to call people names, if in return I am not belittled in posts attacking my concerns. It goes both ways.

I have been in stocks before that showed great promise, but never went anywhere. That is what happens in small biomed penny stocks. By the way, that is what we are! We're not Amgen yet. There are no guarantees that everything will turn out the way Gerald promises. They haven't so far. Many CEO's go down in flames trying to build their fledgling companies. So for those who are smug about AMBS' inevitability and like to lecture us who lack faith and like to question things....I ask that you not be so smug. You don't know but what our concerns may be valid. And the message board is the appropriate place to discuss them...civilly.


Amarantus Bioscience Holdings (AMBS) Stock Research Links

AMBS Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

2027 Toy of the Year Finalists Energize Play Market

Updated Category News Views 272

A Kaleidoscope of Innovation in Toys There's a familiar buzz in the air, folks. The 2027 Toy of the Year Awards finalists have been unveiled, and they're bringing a fresh wave of creativity to children's playrooms. These aren't just toys; they're miniature innovators ready to light up the market this holiday season. The reveal happened at the Chicago Toy & Game Fair and...

Continue Reading
Paris Baguette Pioneers Drive-Thru in Oklahoma

Updated Category News Views 468

Tapping The Unseen Potential In Bakery Cafes Every so often a business move comes along that makes you sit up and say, "Why the hell haven't they done this before?" Paris Baguette has finally cracked that code, rolling out its first-ever drive-thru in Moore, Oklahoma. Now, imagine yourself zipping through for a croissant without leaving the comfort of your car seat. Makes...

Continue Reading
7th World Media Summit Spotlights Media's Future in Beijing

Updated Category News Views 235

The Changing Landscape of Global Media An event of this magnitude doesn't just pop up every day like a stock ticker on Wall Street. This year's 7th World Media Summit in Beijing is where nearly 500 bigwigs from all corners of the media landscape are converging. It's not about trading stocks or hitting quarterly numbers—it's about shaping how stories get told in an era...

Continue Reading
TCL's Display Future: AI Meets Screens at DTC 2026

Updated Category News Views 262

Exploring New Horizons in Display Technology There's something brewing in Wuhan: a conference that’s shaping up like a tech enthusiast’s dream. This year, it's all about the symbiosis of cutting-edge tech and dazzling visuals as TCL CSOT gears up to unveil advancements at the Global Display Tech-Ecosystem Conference (DTC) 2026. If you're wondering whether this event...

Continue Reading
Historic Records Set at 2026 CNO Monumental Marathon

Updated Category News Views 317

Race to Remember: Monumental Breakthroughs In the chilly November air of Indianapolis, the 2026 CNO Financial Indianapolis Monumental Marathon wasn't just another tick on the calendar—this was a banner day for running. With record-breaking performances across every distance, we saw what happens when a community of athletes, sponsors, and volunteers hits a perfect...

Continue Reading
Quantum Space Joins $185M NASA Lunar Transport Deal

Updated Category News Views 347

Quantum Space Bags a Chunk of NASA's Lunar Ambitions Alright, folks, buckle up because we're about to dive into the cosmos. Quantum Space just nabbed a sweet deal—a $185 million whopper of a contract from NASA's Moon Base Transportation program. This isn't chump change; it's a 25% slice for Quantum from the lot Arrow Science and Technology is heading. We're talking...

Continue Reading
J&J's New Study: Sjögren’s Solution Insight Sparks Debate

Updated Category News Views 174

Patient-Centric Take on Sjögren's Disease Johnson & Johnson has dropped fresh Phase 2 results on nipocalimab, reminding everyone they're at the helm of reshaping treatments for Sjögren's disease (SjD). A condition leaving about four million folks craving better days, in multiple ways, shines a light on what's gripping patients the hardest. It's hard not to sit up and...

Continue Reading
JOYEE N01 Kicks Off Global Launch with African Orders

Updated Category News Views 319

A New Chapter for JOYEE N01 There's a moment in every company's life when it either steps boldly into the future or stumbles back into obscurity. For FAW Bestune, October 28, 2026, was one of those defining moments. On this day, they launched global mass production of the JOYEE N01 in Yancheng, China. And boy, did they pull out all the stops—you don't see this kind of...

Continue Reading
Invasive Procedures Don't Extend Life in Stable Heart Disease

Updated Category News Views 299

Challenging Longstanding Beliefs Today’s news from the heart research front might set a few cardiology heads spinning. We’ve got big-time findings out of the ISCHEMIA-EXTEND study, throwing more weight on the evidence pile that early invasive heart procedures for patients with stable coronary artery disease don’t actually extend your life. Managing care with a blend...

Continue Reading
Johnson & Johnson Unveils Promising PsA Treatment Data

Updated Category News Views 235

A Game-Changer in Psoriatic Arthritis Treatment? Johnson & Johnson just tossed a headline-grabbing bone into the world of psoriatic arthritis with their new ICOTYDE results. For anyone tangled in the chronic web of psoriatic arthritis, hearing about a potential new treatment like ICOTYDE comes with cautious hope. Between stiff joints and rashy skin, sufferers are often...

Continue Reading

Top 5 Most Recently Viewed Articles

SAP Reports Stellar Q2 2025 Results: Growth & Innovations

Updated Category News Views 430

SAP Quarterly Performance Highlights for Q2 2025 SAP SE (NYSE: SAP) has reported remarkable growth in its second quarter of 2025, showcasing impressive financial metrics and strong momentum across its cloud services. As a global leader in enterprise applications and business AI, SAP continues to solidify its position in the market as it drives innovation and...

Continue Reading
Fluor Corporation Faces Legal Action Amid Investment Concerns

Updated Category News Views 173

Fluor Corporation and the Recent Legal Developments Fluor Corporation (NYSE: FLR) has been at the center of significant legal developments that concern its investors. Those who have invested in Fluor, particularly between specific dates, are urged to pay attention to important deadlines related to a securities fraud class action lawsuit initiated against the company....

Continue Reading
Celebrating Excellence: CAGC's 2025 Small Business Award

Updated Category News Views 145

A Prestigious Recognition of Hard Work Every industry thrives on the dedication of its members, and in the construction sector, such dedication doesn't go unnoticed. Carolinas AGC recently introduced a significant accolade — the CAGC Small Business Award. This inaugural achievement is dedicated to honoring member firms who demonstrate exceptional commitment and...

Continue Reading
Pacsun Elevates Festival Culture with Innovative Experiences

Updated Category News Views 458

Pacsun's Impact on Festival Culture Pacsun has firmly established itself as a trailblazer in the intersection of fashion and music. As the vibrant festival season approaches, the brand is gearing up to leave an unforgettable impression with its unique and innovative activations. With a focus on connection and engagement, Pacsun is not merely participating in festival...

Continue Reading
Exploring Gold's Resilience Amid Global Uncertain Trends

Updated Category News Views 150

Gold's Performance in 2024: A Year of Unprecedented Growth In 2024, gold demonstrated remarkable resilience and growth, emerging as a beacon during uncertain times. The global landscape, shaped by economic fluctuations and geopolitical tensions, has reinforced gold's status as a trusted store of value. This year, we delve into several interconnected factors that propelled...

Continue Reading